@JessieChimni All this Verve-102 news is being back a ton of old feelings of anger towards getting sold for such a low price and below the IPO price.
English
PinkEyePuddles
1K posts
PinkEyePuddles
@PinkEyePuddles
Speaking truth on the Nets
Katılım Aralık 2022
659 Takip Edilen97 Takipçiler
VERV-102 data helping the entire gene editing space 🥂
English
PinkEyePuddles retweetledi
A huge paper came out yesterday showing a single gene-editing medication dropped LDL 62%!!!
Many were excited that cardiovascular disease and atherosclerosis were defeated, but hold up.
There was an important take home point at the 1 year mark: This study did NOT show improved cardiovascular outcomes.
👀😳🤯
Read that again.
The person’s LDL cholesterol dropped by 62% and yet their cardiovascular health didn’t improve.
My point remains that LDL isn’t the smoking gun here, but that’s besides the point.
The other important thing to understand here is that this was a safety study, not an efficacy study. At 1 year the medication was safe. Curious to see how it does at 3 years, 5 years, 10 years?
Furthermore this was specifically targeting patients with genetic hypercholesterolemia. Super high cholesterol and lipid levels from birth. Not from the standard American diet.
There is something to be excited about here. Nick breaks it down beautifully below, and that’s the proof-of-concept gene editing. That’s where this hits a home run.
The future of medicine is bright!!!
Nick Norwitz MD PhD@nicknorwitz
Will This Gene Editing Breakthrough Eliminate Heart Disease? (And what everyone is missing) 1/6) A massive new study in the New England Journal of Medicine just broke the internet, showing that gene editing lowered LDL cholesterol by 62%. The reactions have been wildly polarized: • “We’re curing heart disease with one shot” • “This is reckless sci-fi nonsense” But almost everyone is missing the bigger story.
English
PinkEyePuddles retweetledi
Lilly acquired VERVE-102 in $1 billion deal with Verve Therapeutics. Gene editing therapy cut LDL cholesterol 62% with no safety issues reported. trib.al/Ai0arsr
English
PinkEyePuddles retweetledi
PinkEyePuddles retweetledi
PinkEyePuddles retweetledi
PinkEyePuddles retweetledi
SITUATION ANALYSIS: the race to prevent heart disease is accelerating.
What @cremieuxrecueil says is happening:
• Multiple companies are targeting LDL
• Some use CRISPR
• Some use epigenetic silencing
• Targets include PCSK9, ANGPTL3, and LDLR
• The goal is a one-shot or long-lasting therapy
• Early promise: massively lower LDL cholesterol
• The big open question is how long the effect lasts
Crémieux@cremieuxrecueil
Eli Lilly has done it. They've gone and made what seems to be a powerful, permanent gene therapy for LDL cholesterol. That means they'll be able to effectively prevent most heart disease with a single infusion!
English
PinkEyePuddles retweetledi
The biggest problem with cholesterol drugs is not the drug, Half of all patients stop taking them within a year.
Lilly VERVE-102 removes the patient from the equation, One infusion edits the PCSK9 gene in your liver, drops LDL cholesterol by up to 62%, and the effect has held for at least 18 months so far.
35 patients in the Phase 1 trial, published in the NEJM, zero serious side effects, This is not a better pill, Compliance is now biology....
Some people are born with their PCSK9 gene naturally turned off, They carry low LDL cholesterol for life and almost never get heart attacks.
Lilly VERVE-102 copies that genetic advantage into anyone through a single IV infusion, In 35 patients, LDL dropped up to 62% and PCSK9 protein fell 88% at the highest dose.
Effect lasted 18 months and counting, Lilly paid $1 billion for Verve Therapeutics to own this, The best medicine does not treat disease - It makes disease irrelevant.
This is Lilly second attempt, The first candidate, VERVE-101, was pulled after a patient died of cardiac arrest and others showed liver damage.
VERVE-102 uses a redesigned delivery system to get the gene editor into liver cells more safely, In 35 patients, it matched the old drug cholesterol reduction with none of the safety problems.
Zero serious side effects across all doses, Phase 2 starts later this year But 35 people is not proof - road is still very long
Crémieux@cremieuxrecueil
Eli Lilly has done it. They've gone and made what seems to be a powerful, permanent gene therapy for LDL cholesterol. That means they'll be able to effectively prevent most heart disease with a single infusion!
English
PinkEyePuddles retweetledi
PinkEyePuddles retweetledi
SITUATION ANALYSIS: Biotech may be entering its miracle era.
What we know:
• Eli Lilly has a new gene therapy targeting LDL cholesterol
• LDL drives atherosclerotic plaque in arteries
• Plaque buildup leads to heart attacks and strokes
• A one-shot therapy could make heart disease much more preventable
• Cancer treatment is also improving fast
• Obesity has already been transformed by GLP-1s
• And this is mostly before AI fully hits drug discovery
@theojaffee: “This is pre-AI, by the way.”
“Once you get actual AIs working on drugs, it’s actually just over for diseases.”
Crémieux@cremieuxrecueil
Eli Lilly has done it. They've gone and made what seems to be a powerful, permanent gene therapy for LDL cholesterol. That means they'll be able to effectively prevent most heart disease with a single infusion!
English
PinkEyePuddles retweetledi
One of the most remarkable findings from the VERVE-102 paper is not just the 62% LDLc reduction observed, but that this is in a *treated* population.
71% were already on high intensity statin, 43% also on ezetimibe. Amazing.
nejm.org/doi/full/10.10…
English
PinkEyePuddles retweetledi
Heart disease kills more people than every cancer combined. Lilly just published Phase 1b data in the NEJM on a single injection that could prevent most of it. Permanently.
The science starts with a genetic accident. A small percentage of people are born with a broken PCSK9 gene. Their livers clear LDL cholesterol so efficiently that researchers tracking them over 15 years found up to 88% fewer coronary events. The effect was so large it looked like a data error.
The reason is timing. Statins lower your cholesterol at age 45. A broken PCSK9 gene lowers it from birth. Decades of low LDL compound into plaque that never forms in the first place. You can't reverse 40 years of arterial damage with a pill. You can prevent it entirely with a gene.
VERVE-102 is a base editor. Single IV infusion. One letter changed in your liver cells' DNA. The PCSK9 gene turns off permanently. Phase 1b results across 35 patients: 88% reduction in PCSK9 protein, 62% drop in LDL cholesterol at the highest dose. Durable at 18 months. The effect didn't fade.
Lilly paid $1.3 billion to acquire Verve Therapeutics for this program. The global statin market does roughly $16 billion a year selling daily pills that patients take for life. If a single infusion replaces 30 years of daily medication, Lilly didn't buy a drug. They bought the retirement plan for an entire drug class.
One shot to join the genetic lottery that most of the population lost.
Crémieux@cremieuxrecueil
Eli Lilly has done it. They've gone and made what seems to be a powerful, permanent gene therapy for LDL cholesterol. That means they'll be able to effectively prevent most heart disease with a single infusion!
English
PinkEyePuddles retweetledi
صحيح .. هذه نتائج مبشره ولله الحمد ، لكن تظل نتائج اوليه فقط في الوقت الراهن و يجب توخي الحذر بسبب صغر حجم العينه من المرضى (٣٥ مريض) ، بالإضافه الى الحاجه إلى متابعة حالتهم الصحيه لسنوات عديده للتأكد من عدم ظهور أعراض جانبيه جديده كونه علاج يقوم بتعديل الجينات الوراثيه 🧬 DNA.
يجب ايضاً اجراء أبحاث طبيه باستخدام هذا الدواء في مرضى من دول أخرى وأعراق مختلفه. قمت بلقاء ومناقشة - عبر اجتماع افتراضي- من شهر تقريبا مع احد العلماء المؤسسين للشركه التي ابتكرت الدواء في مراحله الاوليه وأظهر رغبته في دعوة مراكز بحثيه من السعوديه للدخول في الأبحاث العلميه لهذا الدواء (مما يعكس الثقه العالميه التي وصلت اليها السعوديه من خلال منشآت ومراكز بحثيه وخبرات علميه كبيره في هذا المجال).
عبدالله مشاط@AbdullahMashat
ضربة معلم من Eli Lilly هذا اهم خبر موجود في تويتر حاليًا وممكن يغير حياة مئات ملايين البشر للاحسن منتظر اراء المتخصصين في هذه القفزة الطبية الطب كل ماله بيتحسن وجودة الحياة كذلك
العربية
PinkEyePuddles retweetledi
BREAKING. Today in the New England Journal of Medicine: a single IV infusion permanently dropped LDL cholesterol by up to 62%, with effects sustained 18 months and counting.
This is the beginning of one-shot gene-editing medicine for heart disease.
Eric Topol@EricTopol
Just published @NEJM Marked and durable reduction of LDL cholesterol with one shot PCSK9 gene base editing @skathire nejm.org/doi/full/10.10…
English
PinkEyePuddles retweetledi
Lilly’s new one-shot gene therapy cuts LDL up to 62% long-term.
Pair that with Retatrutide dropping liver fat by 80%+ and we might be looking at real prevention for heart disease + MASLD.
It’s in the early stages, but studies look promising.
What a run Eli Lilly is on!
Crémieux@cremieuxrecueil
Eli Lilly has done it. They've gone and made what seems to be a powerful, permanent gene therapy for LDL cholesterol. That means they'll be able to effectively prevent most heart disease with a single infusion!
English
PinkEyePuddles retweetledi
First, GLP-1s. Now this.
Others will soon follow.
Don’t Die is the sunrise on the horizon.
Crémieux@cremieuxrecueil
Eli Lilly has done it. They've gone and made what seems to be a powerful, permanent gene therapy for LDL cholesterol. That means they'll be able to effectively prevent most heart disease with a single infusion!
English
PinkEyePuddles retweetledi
Would you permanently edit the DNA of cells in your liver in order to lower your LDL cholesterol and your risk of a heart attack?
Eli Lilly spent $1 billion a year ago to Verve Therapeutics, a company founded by cardiologist and geneticist @skathire on just that idea. This morning early data on the company's new experimental gene editor were published in the New England Journal of Medicine and presented at the annual meeting of the European Atherosclerosis Society in Athens.
The treatment lowered LDL, which we know causes heart attacks, by 62% -- about the same amount as 10 mg of rosuvastatin plus ezetimibe. But Kathiresan points out to my colleague Jason Mast that constant LDL-lowering should work better than a pill patients often stop taking.
“I treated patients for about 20 years, and you know, patients ask me all the time whether they’ll be on cholesterol medicine for the rest of their lives,” Kathiresan said. “And I think with VERVE-102 for the first time, I can tell them maybe not.”
Cardiologists say it will take time, data, and experience to know if this approach is right for some people.
There were no treatment-related serious adverse events in the Phase 1 study — a notable finding, given that Verve had to shelve its first candidate due to safety concerns.
GIF
English
PinkEyePuddles retweetledi
Kalpten ölmeden 100 yıl yaşamayı hayal olmaktan çıkaran tedaviler:
GLP-1
ARNİ
PCSK-9 inhibitörleri (siRNA)
SGLT-2 inhibitörleri
Yakın zamanda elimizi güçlendirecek tedavi: PCSK-9 gen terapileri ile kalıcı kolesterol tedavisi
Heyecanlıyız 🩺
Türkçe
PinkEyePuddles retweetledi
This new gene therapy will be the biggest Lilly med ever… bugger than Mounjaro or Reta.
Unreal.
Crémieux@cremieuxrecueil
Eli Lilly has done it. They've gone and made what seems to be a powerful, permanent gene therapy for LDL cholesterol. That means they'll be able to effectively prevent most heart disease with a single infusion!
English